Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics is advancing its drug development significantly, with important milestones and data expected in 2025 and 2026, indicative of ongoing progress in treating complex conditions such as recurrent glioblastoma and leptomeningeal metastases. The company secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to support its research initiatives, which enhances its financial position and supports the viability of its treatment strategies. Additionally, the commercial launch of its assay offers an immediate revenue opportunity while solidifying Plus Therapeutics's strategic role in disease surveillance and early intervention within the clinical landscape.

Bears say

Plus Therapeutics faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the potential failure of its product candidates, such as rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, the company may encounter challenges in securing regulatory approval for commercial sale and obtaining suitable reimbursement for its treatments, which could further hinder revenue generation. Moreover, competition within the pharmaceutical landscape and evolving macroeconomic conditions present additional uncertainties that could adversely impact the company's financial performance.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.